Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 24 Jun 2021
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
24 June 2021 - Today, the Therapeutic Goods Administration granted provisional determination to Moderna Australia in relation to the COVID-19 ...
Posted by Michael Wonder on 24 Jun 2021
National Medicines Policy review to begin in August 2021
24 June 2021 - The review of the National Medicines Policy will begin in August 2021. ...
Posted by Michael Wonder on 23 Jun 2021
Coronavirus Australia: is the vaccine rollout designed to be slow and ineffective?
23 June 2021 - Another day, another COVID-19 outbreak. ...
Posted by Michael Wonder on 23 Jun 2021
Access to medicine: the states with the most and least pharmacies per capita
21 June 2021 - Many people live in pharmacy deserts. ...
Posted by Michael Wonder on 23 Jun 2021
FDA chief under fire over Alzheimer’s drug decision
22 June 2021 - US regulator’s approval of controversial treatment shows it is too close to Big Pharma, say critics. ...
Posted by Michael Wonder on 23 Jun 2021
FDA should lead the way on new ALS treatments, not Canada and Europe
22 June 2021 - Following the FDA’s recent decision to give the green light to aducanumab, the first treatment approved ...
Posted by Michael Wonder on 23 Jun 2021
Evio Pharmacy Solutions established to tackle affordability, outcomes, and experience with medications
22 June 2021 - Privately funded venture will offer innovative medication solutions to patients, providers and customers. ...
Posted by Michael Wonder on 23 Jun 2021
Fees and charges: summary from 1 July 2021
23 June 2021 - The TGA is required to recover its costs for all activities that fall within the scope of ...
Posted by Michael Wonder on 23 Jun 2021
Rare disease patient advocates continue battle for affordable drugs
23 June 2021 - Beth Vanstone, mother of local Cystic Fibrosis Warrior Madi Vanstone and director of the CF Get ...
Posted by Michael Wonder on 23 Jun 2021
AstraZeneca to be phased out of Aussie jab rollout
23 June 2021 - The Melbourne-made AstraZeneca vaccine will be phased out of Australia’s COVID-19 jab rollout later this year. ...
Posted by Michael Wonder on 23 Jun 2021
TGA approves first generic pomalidomide
23 June 2021 - The TGA has approved first generic version of Celgene's Pomalyst. ...
Posted by Michael Wonder on 23 Jun 2021
Aducanumab (Aduhelm) information
22 June 2021 - The FDA has posted the CDER’s Office of Neurology’s Summary Review Memorandum describing the agency’s extensive ...
Posted by Michael Wonder on 23 Jun 2021
Price disclosure 2021 October cycle outcomes summary
23 June 2021 - The summary of price disclosure price reductions for the 2021 October cycle has now been published. ...
Posted by Michael Wonder on 23 Jun 2021
Genmab announces that Janssen has received European marketing authorisations for Darzalex (daratumumab) subcutaneous formulation, including for the treatment of patients with newly diagnosed light-chain amyloidosis
22 June 2021 - Janssen received European approval for Darzalex SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone ...
Posted by Michael Wonder on 23 Jun 2021
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
22 June 2021 - The European Commission regulatory approval is primarily supported by data from the ECZTRA 1, 2 and ECZTRA ...